Ikena Oncology

CIK 0001835579 · Biotech

ikenaoncology.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$43M
2 Form D · Jul 2025
15 months since last filing
Contracts
—
No federal contracts on record
Patents
40
13 granted · 27 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$42,571,751
Private capital raisedForm D · SEC$75,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1184Immunaeon Inc.—$250K
1185Exxel Pharma, INC.—$600K
1186Vivid Genomics, Inc.——
1187Ikena Oncology—$43M
1188SHIP OF THESEUS, LLC——
1189Bridge Therapeutics, Inc.—$321K
1190BioVaxys Technology Corp.—$301K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 12 related persons
  • David BonitaDirector
  • Iain DukesDirector
  • Jeffrey EcsedyExecutive Officer
  • Jean-Francois FormelaDirector
  • Owen HughesDirector
  • Maria KoehlerDirector
  • Mark ManfrediDirector · Executive Officer
  • Jotin MarangoExecutive Officer
  • Sergio SantillanaExecutive Officer
  • Otello StampacchiaDirector
  • Richard WoosterDirector
  • Michelle ZhangExecutive Officer

Patents

USPTO · 13 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.